Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10037457 | 0.90 | MAOA (0.58) | MAOABACE1MAPTALDH1A1TSHR | |
| SCHEMBL16656214 | 0.79 | MAOA (0.70) | MAOABACE1MAPTALDH1A1TSHR | |
| SCHEMBL16656217 | 0.76 | TTR (0.60) | MAOAESR1ESR2BACE1MAPT | |
| Anthrarufin SCHEMBL187843 | 0.75 | MAOA (1.00) | MAOAMAPTALDH1A1TSHRMAPK1 | |
| Anthrarufin SCHEMBL29363946 | 0.75 | MAOA (1.00) | MAOAMAPTALDH1A1TSHRMAPK1 | |
| Anthrarufin SCHEMBL29874705 | 0.75 | MAOA (1.00) | MAOAMAPTALDH1A1TSHRMAPK1 | |
| SCHEMBL10037453 | 0.75 | MAOA (0.58) | MAOAMAPTALDH1A1TSHRMAPK1 | |
| SCHEMBL10037460 | 0.75 | MAOA (0.58) | MAOAMAPTALDH1A1TSHRMAPK1 | |
| SCHEMBL10037462 | 0.73 | MAOA (0.56) | MAOAMAPTALDH1A1TSHRMAPK1 | |
| SCHEMBL10037461 | 0.73 | MAOA (0.56) | MAOAMAPTALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2436669-B1 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-8703979-B2 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO., LTD. (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703979-B2 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO., LTD. (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | NR2C2, NR0B2, NR4A2 | MAOA 1290/4885ESR1 752/4885ESR2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.